Details for Patent: 7,438,927

Which drugs does patent 7,438,927 protect, and when does it expire?

Patent 7,438,927 protects GRALISE and is included in one NDA.

This patent has twenty-four patent family members in nine countries.

Summary for Patent: 7,438,927

Title:	Methods of treatment using a gastric retained gabapentin dosage
Abstract:	A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form.
Inventor(s):	Berner; Bret (El Granada, CA), Hou; Sui Yuen Eddie (Foster City, CA), Gusler; Gloria M. (Cupertino, CA)
Assignee:	Depomed, Inc. (Menlo Park, CA)
Application Number:	10/280,309
Patent Claim Types: see list of patent claims	Use; Dosage form; Formulation;

Drugs Protected by US Patent 7,438,927

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Almatica	GRALISE	gabapentin	TABLET;ORAL	022544-001	Jan 28, 2011	AB2	RX	Yes	Yes						TREATMENT WITH GABAPENTIN, INCLUDING TREATMENT OF NEUROPATHIC PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH POSTHERPETIC NEURALGIA
Almatica	GRALISE	gabapentin	TABLET;ORAL	022544-002	Jan 28, 2011	AB2	RX	Yes	No						TREATMENT WITH GABAPENTIN, INCLUDING TREATMENT OF NEUROPATHIC PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH POSTHERPETIC NEURALGIA

International Family Members for US Patent 7,438,927

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2002348828
Australia	2005267738
Australia	2006332690
Canada	2464322